Sunovion Pharmaceuticals Inc.

Sepracor, Inc.

Seth C Hopkins

Kenneth S Koblan

John R Snoonian

Harold Scott Wilkinson

Milan Chytil

Kerry Leigh Spear

Q Kevin Fang

Michele Heffernan

Qun Kevin Fang

Brian M Aquila

Michele L R Heffernan

Fengjiang Wang

Robert J Foglesong

Curtis A Lockshin

Yuki Tsushima

Mustapha Soukri

Siriporn Toongsuwan

Takumi Asada

Gerald R Galluppi

Megumi Maruyama

Cyprian Okwara Ogbu

Peter Wipf

Una Campbell

Paul T Grover

Frank Wu

Mark A Varney

James Michael Dorsey

Carrie A Bowen

Steven W Jones

Antony Loebel

Ajay Ogirala

Colleen M Synan

Brian A Aquila

Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

Modified release formulations and uses thereof

Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

Nonracemic mixtures and uses thereof

The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

Methods of treating neurological and psychiatric disorders

Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.

Methods of treating schizophrenia

Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed. Many of the compounds disclosed herein may be represented by the following generic formula: 

Imidazo[1,2-a]pyridine compounds

The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.

Inhibitors of D-amino acid oxidase

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein

Pyrrole and pyrazole DAAO inhibitors

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CRand N. X and Y are members independently selected from O, S, CR, N and NH. R, Rand Rare members independently selected from H and F, provided that at least one member selected from R, Rand Ris F. Ris a member selected from OXand OH, wherein Xis a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

Fluoro-substituted inhibitors of D-amino acid oxidase

Growing community of inventors

Clinton, MA, United States of America

Seth C Hopkins